Hepatitis C Treatment in Bangkok | DAA Cure at Take Care Clinic

Hepatitis C treatment in Bangkok has changed dramatically over the past decade. The hepatitis C virus (HCV), once a chronic, lifelong infection that quietly scarred the liver over years, is now curable in more than 95% of people who complete a short, effective course of direct-acting antiviral (DAA) drug therapy lasting just 2 to 3 months. At Take Care Clinic on Sukhumvit Soi 13, we test, stage, and treat HCV infection on an outpatient basis for residents, expats, and medical travelers across Bangkok and Thailand.

What hepatitis C is and why it matters

Hepatitis C is a viral infection that targets the liver. Most people with acute infection have no symptoms; roughly three out of four go on to develop chronic hepatitis C, where the virus persists in the blood for years and slowly damages liver tissue. Untreated chronic HCV may progress to cirrhosis, liver failure, and hepatocellular carcinoma (liver cancer), and the World Health Organization estimates that around 50 million people are living with chronic HCV worldwide, only a fraction know their status.

HCV is blood-borne. The main routes of exposure are use of shared injection equipment, unsterile tattooing or body piercing, healthcare exposure before universal screening of donated blood, sharing razors or toothbrushes with an infected person, and less efficiently sexual transmission, particularly among men who have sex with men and people co-infected with HIV. Casual contact, food, water, kissing, and mosquito bites do not transmit the virus.

Hepatitis C in Thailand

Thailand carries a meaningful HCV burden. Older Thai birth cohorts who received healthcare or transfusions before the 1990s screening era, people who inject drugs, and people co-infected with HIV form the bulk of cases. Genotypes 1a, 1b, 3, and 6 are all common in the kingdom. Modern pangenotypic DAAs treat all genotypes with the same regimen, and generic sofosbuvir and ledipasvir/sofosbuvir are widely available in Thailand at favorable prices compared with Western markets. International patients often travel to Bangkok specifically to complete a cure at a fraction of US or European costs.

Testing for hepatitis C

HCV testing is a two-step process. The screening test is the HCV antibody (anti-HCV) blood test, which detects whether you have ever been exposed to the virus. Antibodies persist for life even after spontaneous clearance or successful cure, so a reactive result does not by itself confirm current infection. The confirmatory test is the HCV RNA (PCR) test, which measures whether the virus is actively replicating in your blood right now. Only a positive RNA result confirms chronic hepatitis C requiring treatment.

We offer both tests at the clinic, with results typically returned within 24 to 72 hours depending on the assay used. The WHO and US CDC both recommend at least one lifetime HCV screen for every adult, plus repeat testing for anyone with ongoing risk factors. We also run hepatitis C testing as part of our comprehensive sexual health screening panel, alongside HIV testing, syphilis, gonorrhea, chlamydia, and hepatitis B.

Staging liver disease

Once HCV infection is confirmed, the next step is to stage the liver. This determines how aggressive the disease is, which treatment regimen is appropriate, and how long therapy needs to run. Standard staging at our clinic includes full blood count, liver function tests (ALT, AST, bilirubin, albumin), kidney function, INR, HIV and hepatitis B screening, and a non-invasive fibrosis measure, typically FibroScan (transient elastography) or a calculated APRI or FIB-4 score from blood. Patients with significant fibrosis or cirrhosis need additional surveillance for liver cancer, including six-monthly ultrasound and alpha-fetoprotein (AFP) testing, and a referral to a hepatologist where appropriate.

Direct-acting antiviral (DAA) treatment

The current standard of care is an oral, pangenotypic DAA regimen taken once daily for 8 to 12 weeks. The two regimens used most often in Thailand are sofosbuvir/velpatasvir (12 weeks) and glecaprevir/pibrentasvir (8 weeks in treatment-naive patients without cirrhosis). Both achieve sustained virological response (SVR), the modern definition of cure, in more than 95% of people. Tablets are taken with or without food, side effects are typically mild (headache, fatigue, mild nausea), and most patients continue normal work and travel throughout the course. Treatment is extended to 16 weeks in selected patients with decompensated cirrhosis or prior DAA failure, who are managed under specialist hepatology supervision.

Monitoring and confirming cure

We monitor patients at week 4 of therapy with repeat liver function tests and a check on adherence and side effects. The decisive test is performed 12 weeks after the final tablet: an HCV RNA PCR. An undetectable result at that point, known as SVR12, defines cure. Cure is permanent: the virus does not reactivate, and the patient cannot transmit HCV through any of the usual routes. Reinfection is possible if exposure continues, so we counsel patients about ongoing risk reduction. Liver damage already present at the time of cure does not reverse fully, so cirrhotic patients continue lifelong liver cancer surveillance after SVR12.

Co-infection and special populations

HCV/HIV co-infection accelerates liver disease and complicates drug interactions; co-infected patients are treated using DAA regimens carefully selected to avoid antiretroviral conflicts. Patients on PrEP or PEP medications who screen positive for hepatitis C should mention this at consultation so we can coordinate care. HBV/HCV co-infection requires monitoring for hepatitis B reactivation during DAA therapy. Chronic kidney disease and pregnancy each modify regimen choice and timing.

Cost and what to expect at the clinic

An initial consultation includes history, examination, and blood draw for screening and staging. Pricing varies with which tests are ordered; the clinic provides a written estimate before any test or prescription. Generic DAA therapy in Thailand is significantly cheaper than branded equivalents in the US or Europe. International patients flying in should plan an initial visit to confirm diagnosis and staging, a script for the full course of medication, and a follow-up plan that can be split between in-person visits and remote check-ins. We can also arrange a doctor hotel visit for patients who prefer a discreet in-room consultation, or an IV drip for those with associated dehydration or fatigue.

When to seek urgent care

Most HCV care is outpatient, but some presentations need same-day assessment: jaundice with confusion or severe abdominal pain, vomiting blood, black tarry stools, or rapidly worsening leg or abdominal swelling. These can signal acute hepatitis, decompensated cirrhosis, or variceal bleeding. Patients with these features should attend our clinic during open hours or proceed to a hospital emergency department. For acute non-hepatitis presentations during business hours we offer walk-in urgent care; severe presentations should go directly to a tertiary hospital.

Frequently asked questions

Is hepatitis C curable? Yes. Modern DAA therapy cures more than 95% of people who complete a 8-12 week course, including those with cirrhosis and HIV co-infection.

How long does treatment take? Most patients complete a single oral regimen lasting 8 or 12 weeks. SVR12 is confirmed 12 weeks after the last tablet.

Do I need a liver biopsy? No. FibroScan (transient elastography) and blood-based scores (APRI, FIB-4) have largely replaced biopsy for staging fibrosis in HCV.

Can I drink alcohol during treatment? We strongly recommend avoiding alcohol during DAA therapy and minimising alcohol thereafter, alcohol accelerates liver damage and undermines the benefit of cure.

Can I travel during treatment? Yes. DAAs are well tolerated and you can travel normally; bring your tablets in original packaging and carry a clinic letter for customs if needed.

Is HCV testing included in a standard sexual health panel? It can be. Ask for it explicitly as part of our STD treatment and testing service.

References

1. World Health Organization. Hepatitis C fact sheet, 2024. who.int/news-room/fact-sheets/detail/hepatitis-c
2. American Association for the Study of Liver Diseases (AASLD) / Infectious Diseases Society of America (IDSA). HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. hcvguidelines.org
3. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73(5):1170-1218.
4. US Centers for Disease Control and Prevention. Hepatitis C, clinical overview and screening recommendations. cdc.gov/hepatitis-c
5. Thai Association for the Study of the Liver. Thailand practice guideline for management of chronic hepatitis C, latest revision.
6. Hill A, et al. Minimum costs to produce hepatitis C direct-acting antivirals, implications for global access. J Virus Erad. Updated analyses through 2023.

Medically reviewed by Dr Ponlawat Pitsuwan, MD.